体细胞BRCA1/2突变与生殖系对应突变在输卵管卵巢高级别浆液性癌中具有相似的生存优势
该研究利用两个队列(队列1 n=174,队列2 n=279)和TCGA-OV外部验证(n=316),发现HRR突变患者生存期延长;gBRCA1/2与sBRCA1/2相比HRR野生型生存获益相似;非BRCA HRR突变与显著生存优势相关。
要点
- HRR突变(BRCA1、BRCA2、非BRCA HRR突变)患者在两个队列中均显示生存期延长。
- gBRCA1/2与sBRCA1/2相比HRR野生型生存获益相似,并在TCGA-OV数据集中重现。
- 非BRCA HRR突变与显著生存优势相关,且与高HRDetect评分相关。
核心结论
- gBRCA1/2与sBRCA1/2在与生存期延长的关联上等效。
- 非BRCA HRR基因突变可能与HGSOC中显著有利的生存相关。
研究设计与样本
- 研究使用两个患者队列:队列1(n=174)为匹配的FFPE肿瘤与正常组织,采用基于面板的测序;队列2(n=279)为匹配的新鲜肿瘤与正常组织,采用全基因组测序。
- TCGA-OV样本(n=316)用于外部验证。
主要发现
- HRR突变肿瘤患者(BRCA1、BRCA2、非BRCA HRR突变)在两个队列中均显示生存期延长:队列1多变量风险比(multiHR)0.53(0.32-0.87);队列2 multiHR 0.36(0.25-0.51)。
- 在合并队列(队列1+2)中,gBRCA1/2与sBRCA1/2相比HRR野生型组生存获益相似:gBRCA1/2 multiHR 0.50(0.34-0.71);sBRCA1/2 multiHR 0.41(0.25-0.68)。
- TCGA-OV数据集重现上述发现:gBRCA1/2 multiHR 0.56(0.34-0.91);sBRCA1/2 multiHR 0.48(0.25-0.92)。
- 非BRCA HRR突变与显著生存优势相关(相比HRR野生型multiHR 0.22(0.11-0.45))。
- BRCA1突变病例(生殖系或体细胞)的生存优势较不明显(非BRCA HRR突变 vs BRCA1突变 multiHR 0.41(0.19-0.90))。
关键数值与推荐
- gBRCA1/2、sBRCA1/2和非BRCA HRR突变均与高HRDetect评分相关(中位数1.00 vs HRR野生型0.56,P < 0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Half of high grade serous tubo-ovarian carcinomas (HGSOC) demonstrate homologous recombination repair (HRR) deficiency, most commonly through germline or somatic pathogenic variants in BRCA1/2 (gBRCA1/2 or sBRCA1/2). gBRCA1/2 is associated with favourable survival, greater response rate to platinum-based chemotherapy, and marked sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. sBRCA1/2 has been assumed to confer a similar clinical phenotype; however, few studies have specifically investigated sBRCA1/2 versus gBRCA1/2 to demonstrate their equivalence. METHODS: We investigated the association of gBRCA1/2, sBRCA1/2 and non-BRCA HRR gene mutations with HGSOC patient survival using two patient cohorts (cohort 1, n = 174 matched FFPE tumour and normal with panel-based sequencing; cohort 2, n = 279 matched fresh tumour and normal with whole genome sequencing). TCGA-OV samples (n = 316) were used for external validation. RESULTS: Patients with HRR-mutant tumours (BRCA1, BRCA2, non-BRCA HRR-mutant) demonstrated prolonged survival across both cohorts (cohort 1: multivariable hazard ratio [multiHR] 0.53 [0.32-0.87]; cohort 2: multiHR 0.36 [0.25-0.51]). gBRCA1/2 and sBRCA1/2 were associated with a similar survival benefit compared to the HRR-wildtype group in the combined cohort (cohort 1 +2) (gBRCA1/2: multiHR 0.50 [0.34-0.71]; sBRCA1/2: multiHR 0.41 [0.25-0.68]). These findings were recapitulated using the TCGA-OV dataset (gBRCA1/2: multiHR 0.56 [0.34-0.91]; sBRCA1/2: multiHR 0.48 [0.25-0.92]). Non-BRCA HRR mutations were associated with marked survival advantage (multiHR vs HRR-wildtype 0.22 [0.11-0.45]). The survival advantage in BRCA1-mutant cases (germline or somatic) was less marked (multiHR for non-BRCA HRR-mutant vs BRCA1-mutant 0.41 [0.19-0.90]). gBRCA1/2, sBRCA1/2 and non-BRCA HRR mutations were all associated with high HRDetect scores measuring HRR deficiency (median 1.00 versus 0.56 in HRR-wildtype, P < 0.01). CONCLUSION: gBRCA1/2 and sBRCA1/2 are equivalent in their association with prolonged survival. Non-BRCA HRR gene mutations may be associated with markedly favourable survival in HGSOC.
引用
- Hollis RL, Churchman M, Grimes GR, et al. Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma. Eur J Cancer. 2025. PMID: 39955805. doi:10.1016/j.ejca.2025.115299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。